The launch of a new time always brings about numerous changes to programs in the medical billing and rendering world. In 2023, still, some medical billing and rendering changes have created confusion among providers and suppliers. A breakdown of these changes will help providers navigate the streamlined programs.

New Modifier JZ-Effective January 1, 2023

Effective January 1, 2017, CMS needed that providers use the modifier JW( medicine quantum discarded not administered to any case) to report discarded quantities of single- cure vessel medicines to gain payment for the volume discarded. When a provider administers a tradition from a single- cure vessel to a Medicare devisee, CMS provides payment for the administered and discarded quantities.

The discarded quantum is any quantum that isn’t part of the specified cure and isn’t intended to have a remedial effect on the case. generally, the labeled quantum on the medicine vessel minus the lozenge administered equals the discarded quantum.

Because CMS observed low compliance with JW modifier operation in the history and because the discarded medicine refund quantities calculate on this data, CMS has established a separate modifier, JZ( zero medicine quantum discarded not administered to any case), to be reported on claims for single- cure packaged medicines to attest when there are no discarded quantities. The JZ modifier is effective January 1, 2023, but is n’t needed on claims until July 1, 2023. Claims with medicines from single- cure holders without the JZ or JW modifier after July 1 may be subject to provider checkups. Claims that don’t report the modifiers as applicable on or after October 1, 2023, may be returned as unfit to be reused.

Applicable Settings for the JW and JZ Modifiers

CMS requires the JW and JZ modifiers for providers and suppliers who buy and bill independently outstanding medicines under Medicare Part B. This generally occurs in croaker ’s services, inpatient settings, and critical access hospitals for heirs who admit medicines incident to croakers ’ services. This demand doesn’t extend to pastoral health conventions, federally good health centers, or sanitarium outpatient admissions that providers bill under the Inpatient Prospective Payment System.

Applicable Use of Modifier JW

When a provider administers a single- cure vessel, and there are discarded quantities, the provider must file a claim with two lines for the medicine. Both line particulars will be reused for payment

One claim line must include the billing and payment law( similar as a Healthcare Common Procedure Coding System law( HCPCS)) with no modifier and the number of units administered in the unit field.
The alternate claim line must include the same billing and payment law as the former bone . still, providers must attach modifier JW and include the number of units discarded in the unit field.
Applicable Use of Modifier JZ
When a provider administers a single- cure vessel medicine, and there are no discarded quantities, the provider must file a claim with one line for the medicine.

The claim line must include the billing and payment law( similar as an HCPCS law), the JZ modifier, and the number of units administered in the units ’ field.
New Billing and Coding Processes Around Discarded medicine Amounts
CMS has no specific conditions regarding the system, format, or where the discarded quantum of the medicine is proved within the EHR. still, CMS expects providers to maintain accurate medical records regarding medicine waste for every devisee.

installations may need to introduce new processes so that the information regarding medicine waste flows efficiently from clinicians to the coding and billing staff. Some EHRs allow the clinician to input the lozenge into an order set, also complete and document an bus computation of the waste on the order set.

CMS will accept an automatic computation of discarded quantities if the discarded quantum is directly proved. Some rendering or billing systems may bus- colonize medicine canons with applicable modifiers grounded on information within the EHR.

For illustration, a installation’s EHR may not allow for this type of robotization and ca n’t be customized to bus- calculate waste and bus- colonize the waste modifiers. In this case, associations need to consider the following factors

Who’ll validate this information, and when will they validate it during the case’s visit?
How will they validate it? Will the provider manually calculate the waste every time, or can they make standardization into the record when the waste for certain types of medicines is harmonious for every case?
Where in the record will providers validate the waste? The attestation needs to be fluently accessible to whoever is rendering the record.
The Bottom Line Be harmonious
thickness is critical to a successful process and reducing crimes and detainments in billing and coding.

For more detailed information from CMS regarding discarded medicines and biologicals and modifiers JW and JZ, see these lately published constantly asked questions Discarded medicines and Biologicals – JW Modifier and JZ Modifier Policy.

CMS Reverses 340B Payment Cuts for 2023
In addition to its periodic medical billing and rendering updates, CMS released the 2023 Inpatient Prospective Payment System( OPPS) Final Rule for the New Year. The rearmost OPPS final rule countries that beginning January 1, 2023, Medicare will pay 340B hospitals under Medicare Part B for certain inpatient medicines( high- cost, independently paid medicines) at the same average deals price( ASP) rate it uses fornon-340B hospitals. This rate is generally original to the medicine’s ASP plus 6.

This new policy reverses former payment cuts where Medicare paid most 340B hospitals for independently paid Part B medicines at a rate generally equal to ASP disadvantage22.5. This reversal is due to a decision by the Supreme Court in American Hospital Association etal.v. Becerra, which set up that CMS’s payment policy in former times wasn’t allowed under the Medicare enactment.

Although the payment cuts have been reversed, CMS is continuing the 340B modifier policy. Modifiers TB( medicine or natural acquired with 340b medicine pricing program reduction, reported for instructional purposes for select realities), which is used by pastoral sole community hospitals, children’s hospitals, and PPS-pure cancer hospitals, and modifier JG( medicine or natural acquired with 340b medicine pricing program reduction, reported for instructional purposes), which OPPS installations use, will still be used on 340B medicine claims.

The operation of the below modifiers will no longer spark a payment reduction. still, CMS will use them for instructional purposes. When billing for waste, providers should bill the discarded medicine quantum on a separate claim line with the applicable TB/ JG modifier added first, followed by the JW/ JZ modifier.

New Canons for Biosimilars
CMS has also added new medicine canons biosimilars as part of the 2023 CPT/ HCPCS law set release. Biosimilars are FDA- approved specifics similar to other specifics in efficacity, operation, implicit side goods, and lozenge. generally, biosimilars bring lower than the original birth.

To support biosimilar product and drive down medicine costs, CMS will repay biosimilars with an ASP lower than or equal to the reference natural price at ASP plus 8, as opposed to the regular natural payment of ASP plus 6. This 2 increase for a biosimilar medicine started on October 1, 2022, and will continue for five times.

Vitalware ® by Health Catalyst druggies can learn further about canons for biosimilars on the Vitalware dashboard under “ Reference Documents ” in the train “ NDC to HCPCS Crosswalk for Manufacturer Specific Biosimilars CY2023. ” This document crosswalks the public medicine law( NDC) to the HCPCS law for the biosimilar to prop in using these new canons.